Sarker Debashis, Reid Alison H M, Yap Timothy A, de Bono Johann S
Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom.
Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28.
Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the rapidly evolving therapeutic implications of targeting it. In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers.
尽管我们对前列腺癌生物学基础的理解最近取得了进展，但该疾病的管理，尤其是在去势抵抗阶段，仍然是一项重大挑战。磷脂酰肌醇3-激酶途径的失调在前列腺癌发生过程中的作用越来越受到关注。在本综述中，我们详细阐述了该途径在前列腺癌发病机制中的作用以及靶向该途径迅速发展的治疗意义。特别是，我们强调了适当选择药物和联合用药的重要性，以及预测性和药效学生物标志物的关键作用。
